NCT05497557View on ClinicalTrials.gov

A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 14, 2022

Primary Completion Date

September 8, 2022

Study Completion Date

September 8, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

Omeprazole

Omeprazole will be administered as an oral capsule.

DRUG

Sotorasib

Sotorasib will be administered as an oral tablet.

Trial Locations (1)

75247

Labcorp Clinical Research Unit Inc., Dallas

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT05497557 - A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers | Biotech Hunter | Biotech Hunter